Precision Treatment of Recurrent/Metastatic Salivary Gland Carcinoma Guided by Molecular Typing
Conditions
- Salivary Gland Carcinoma
- Precision Therapy
Interventions
- DRUG: Cohort 1 (HER2-positive, RC48-ADC)
- DRUG: Cohort 2 (NTRK-fusion or NTRK-mutant)
- DRUG: Cohort 3 (AR-positive, leuprolide + bicalutamide + abiraterone)
- DRUG: TROP2 ADC
- DRUG: TKI
- DRUG: Albumin-paclitaxel + platinum
- DRUG: Albumin-paclitaxel + carboplatin + apatinib + camrelizumab
- DRUG: albumin-bound paclitaxel+trastuzumab+pyrotinib
- DRUG: HER2,trastuzumab deruxtecan± pertuzumab
- DRUG: AR,AR antagonist ++ goserelin + pertuzumab + trastuzumab
- DRUG: AR,AR antagonist +goserelin +docetaxel
- DRUG: ivonescimab + investigator-choice platinum doublet+
- DRUG: iparomlimab + tuvonralimab
- DRUG: cadonilimab
- DRUG: CDK4/6 inhibitor+AI or fulvestrant
- DRUG: alpelisib+fulvestrant
- DRUG: PARP inhibitor
- DRUG: enfortumab vedotin
- DRUG: HER2, pyrotinib + pertuzumab/trastuzumab
- DRUG: vebecotutamab ±lenvatinib
Sponsor
Peking Union Medical College
Collaborators